XML 17 R38.htm IDEA: XBRL DOCUMENT
v3.20.1

Mezzanine and Shareholders' Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
Schedule of Stock Option Transactions Under Stock Option Plans | Outstanding stock options granted to primary care physicians to purchase shares of APC’s common stock consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Options outstanding at January 1, 2017 | 1,910,400 |  |  | $ | 0.167 |  |  | 2.75 |  |  | $ | 1.1 |
Options granted | — |  |  | — |  |  | — |  |  | — |
Options exercised | (1,056,600 | ) |  | 0.167 |  |  | — |  |  | (0.6 | )
Options forfeited | — |  |  | — |  |  | — |  |  | — |
Options outstanding at December 31, 2017 | 853,800 |  |  | $ | 0.167 |  |  | 1.75 |  |  | $ | 0.5 |
Options granted | — |  |  | — |  |  | — |  |  | — |
Options exercised | — |  |  | — |  |  | — |  |  | — |
Options forfeited | — |  |  | — |  |  | — |  |  | — |
Options outstanding at December 31, 2018 | 853,800 |  |  | $ | 0.167 |  |  | 0.75 |  |  | $ | 0.5 |
Options granted | — |  |  | — |  |  | — |  |  | — |
Options exercised | — |  |  | — |  |  | — |  |  | — |
Options forfeited | (853,800 | ) |  | 0.167 |  |  | — |  |  | (0.5 | )
Options outstanding and exercisable at December 31, 2019 | — |  |  | $ | — |  |  | — |  |  | $ | — |
The Company’s outstanding stock options consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Options outstanding at January 1, 2017 | — |  |  | $ | — |  |  | — |  |  | $ | — |
Options assumed in the Merger (see Note 3) | 1,141,040 |  |  | 3.95 |  |  | 5.85 |  |  | 22.6 |
Options granted | — |  |  | — |  |  | — |  |  | — |
Options exercised | — |  |  | — |  |  | — |  |  | — |
Options forfeited | — |  |  | — |  |  | — |  |  | — |
Options outstanding at December 31, 2017 | 1,141,040 |  |  | $ | 3.95 |  |  | 5.79 |  |  | $ | 22.6 |
Options granted | 155,000 |  |  | 9.85 |  |  | — |  |  | — |
Options exercised | (639,800 | ) |  | 4.11 |  |  | — |  |  | 9.8 |
Options forfeited | (9,000 | ) |  | 3.41 |  |  | — |  |  | — |
Options outstanding at December 31, 2018 | 647,240 |  |  | $ | 5.62 |  |  | 4.13 |  |  | $ | 9.2 |
Options granted | 279,698 |  |  | 17.24 |  |  | — |  |  | — |
Options exercised | (241,214 | ) |  | 6.09 |  |  | — |  |  | 2.7 |
Options forfeited | (78,378 | ) |  | 17.62 |  |  | — |  |  | — |
Options outstanding at December 31, 2019 | 607,346 |  |  | $ | 9.22 |  |  | 3.42 |  |  | $ | 5.6 |
Options exercisable at December 31, 2019 | 439,776 |  |  | $ | 4.58 |  |  | 2.09 |  |  | $ | 5.6 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | During the year ended December 31, 2019, the Company granted 145,228 and 56,092 five year stock options to certain ApolloMed board members and executives, respectively, with exercise price ranging from $15.35 - $18.11 and $18.91, respectively, which were recognized at fair value, as determining using the Black-Scholes option pricing model and following:
December 31, 2019 |  | Board Members |  | Executives
Expected Term |  | 3.0 years |  |  | 3.0 years |
Expected volatility |  | 90.50% - 100.27% |  |  | 84.42 | %
Risk-free interest rate |  | 1.60% - 2.51% |  |  | 1.65 | %
Market value of common stock |  | $15.35 - $18.11 |  |  | $ | 18.91 |
Annual dividend yield |  | — | % |  | — | %
Forfeiture rate |  | 0 | % |  | 0 | %
The stock options under the Exclusivity Amendment Agreement were accounted for at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:
| Years ended December 31,
| 2018 |  | 2017
Expected term | 0.75 years |  | 0.93 - 1.75 years
Expected volatility | 38.10% - 41.60% |  | 38.10% - 41.60%
Risk-free interest rate | 1.64% - 1.86% |  | 1.64% - 1.86%
Market value of common stock | $0.52 - $0.76 |  | $0.52 - $0.76
Annual dividend yield | 2.23% - 3.53% |  | 2.23% - 3.53%
Forfeiture rate | 0% - 6.8% |  | 0% - 6.8%
Summary of Share-Based Compensation Expense of Stock Option Awards Granted | Share-based compensation expense related to option awards granted to primary care physicians with Exclusivity Agreements to purchase shares of APC’s common stock, are recognized over their respective vesting periods, and consisted of the following:
| Years ended December 31,
| 2019 |  | 2018 |  | 2017
Share-based compensation expense: |  |  |  |  |
General and administrative | $ | 607,146 |  |  | $ | 809,528 |  |  | $ | 2,113,116 |
| $ | 607,146 |  |  | $ | 809,528 |  |  | $ | 2,113,116 |
Schedule of Warrants Outstanding | The Company’s outstanding warrants consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (In Millions)
Warrants outstanding at January 1, 2017 | — |  |  | $ | — |  |  | — |  |  | $ | — |
Warrants assumed in the Merger | 1,898,541 |  |  | 9.06 |  |  | 2.69 |  |  | 1.8 |
Warrants granted (see Note 3) | 1,750,000 |  |  | 10.49 |  |  | 5.00 |  |  | — |
Warrants outstanding at December 31, 2017 | 3,648,541 |  |  | $ | 9.75 |  |  | 3.74 |  |  | $ | 52.0 |
Warrants granted | — |  |  | — |  |  | — |  |  | — |
Warrants exercised | (286,357 | ) |  | 7.84 |  |  | — |  |  | 3.0 |
Warrants forfeited | (30,189 | ) |  | 4.50 |  |  | — |  |  | — |
Warrants outstanding at December 31, 2018 | 3,331,995 |  |  | $ | 9.93 |  |  | 2.97 |  |  | $ | 33.1 |
Warrants granted | — |  |  | — |  |  | — |  |  | — |
Warrants exercised | (177,405 | ) |  | 9.32 |  |  | — |  |  | 1.60 |
Warrants forfeited | — |  |  | — |  |  | — |  |  | — |
Warrants outstanding at December 31, 2019 | 3,154,590 |  |  | $ | 9.96 |  |  | 2.01 |  |  | $ | 26.7 |
Exercise Price Per Share |  | Warrants Outstanding |  | Weighted Average Remaining Contractual Life |  | Warrants Exercisable |  | Weighted Average Exercise Price Per Share
$ | 9.00 |  |  | 948,498 |  |  | 0.79 |  | 948,498 |  |  | $ | 9.00 |
10.00 |  |  | 1,386,083 |  |  | 2.30 |  | 1,386,083 |  |  | 10.00 |
11.00 |  |  | 820,009 |  |  | 2.94 |  | 820,009 |  |  | 11.00 |
$ 9.00 –11.00 |  | 3,154,590 |  |  | 2.01 |  | 3,154,590 |  |  | $ | 9.96 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration